Sector News

Stryker eyes deals, market share growth in Europe

January 15, 2015
Life sciences
(Reuters) – Orthopedic device and surgical equipment maker Stryker Corp said on Wednesday it is eyeing growth through acquisitions, and has set its sights on improving market share for its products in Europe.
Stryker Chief Executive Kevin Lobo, speaking at the JP Morgan healthcare conference in San Francisco, said the company was in a very strong cash position that would allow it to make acquisitions that are “small, medium or even large.”
“We need to be market leaders in the areas that we choose to play in,” Lobo said. “We’ll look at deals of all different sizes … to strengthen our position.”
Stryker plans to repatriate some $2 billion in cash held overseas in the second half of 2015.
The company on Tuesday cautioned that the strength of the U.S. dollar versus overseas currencies would take a larger than previously expected toll on 2015 earnings, shaving some 20 cents from per share profit versus its prior view of 10 to 12 cents.
Stryker currently has about two thirds of its total sales in the United States, with about a quarter coming from other developed markets and 8 percent from emerging markets.
Lobo sees Europe as a critical area with room for improving Stryker’s performance, and said he believes the capital spending climate there is improving.
“Our market shares are dramatically lower in Europe than in the U.S., Canada or Japan,” he said. “Our products should be garnering higher market share there.”
Stryker has altered its corporate structure so that operations in Europe will now report directly to the United States.
Despite the challenging environment in some emerging markets, such as Russia, Lobo said Stryker aims to increase its percentage of total sales from developing markets “to get to double digits in the next few years.”
Stryker shares were down $2.20, or 2.3 percent, at $92.02 on the New York Stock Exchange.
(Reporting by Bill Berkrot in New York; Editing by Bernard Orr)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]